Atea Pharmaceuticals (NASDAQ:AVIR) Releases Earnings Results, Beats Expectations By $0.28 EPS

Atea Pharmaceuticals (NASDAQ:AVIR) announced its quarterly earnings results on Wednesday. The company reported ($0.48) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.28, Zacks reports. During the same quarter last year, the company earned ($0.34) earnings per share.

Atea Pharmaceuticals Stock Up 0.6 %

Shares of AVIR traded up $0.02 during trading hours on Friday, reaching $3.52. The stock had a trading volume of 35,943 shares, compared to its average volume of 341,467. The company has a market cap of $296.46 million, a P/E ratio of -1.79 and a beta of 0.17. Atea Pharmaceuticals has a 52 week low of $2.77 and a 52 week high of $4.60. The firm has a 50-day moving average of $3.57 and a 200 day moving average of $3.80.

Insiders Place Their Bets

In other Atea Pharmaceuticals news, Director Bruce Polsky sold 17,544 shares of the stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $3.49, for a total value of $61,228.56. Following the completion of the sale, the director now directly owns 65,606 shares in the company, valued at $228,964.94. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 17.80% of the company’s stock.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.